1 |
Vidarsdottir, S., Roelfsema, F., Streefland, T., Holst, J., Rehfeld, J., Pijl, H., 2010. Short-term treatment with olanzapine does not modulate gut hormone secretion; olanzapine disintegrating vs standard tablets, Eur J. Endocrinol., 204(1-3), 190-8.
|
2 |
Hoffmann, V.P., Case, M., Jacobson, J.G., Francis, J.L., 2009. Listing of metabolic changes in healthy volunteers receiving orally dissolving olanzapine or oral olanzapine: Data from a clinical study that was terminated early, Schizophr Res., 115(2-3), 370-1.
DOI
|
3 |
Hori, H., Ueda, N., Yoshimura, R., Yamamoto, H., Wani, K., Etoh, Y., Haraga, K., Kitahara, J., Nakamura, J., 2009. Olanzapine orally disintegrating tablets (Zyprexa ) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: An open-label prospective study, World J. Biol. Psychiatry. 25, 1-5.
|
4 |
Karagianis, J., Grossman, L., Landry, J., Reed, V.A., de Haan, L,, Maguire, G.A., Hoffmann, V.P., Milev, R., 2009. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study, Schizophr Res. 113(1), 41-8.
DOI
|
5 |
Lui, S.Y., Tso, S., Lam, M., Cheung, E.F., 2009. Possible olanzapine- induced hepatotoxicity in a young Chinese patient, Hong Kong Med J. 15(5), 394-6.
|
6 |
Mendhekar, D.N. and War, L. 2009. Olanzapine induced acute Meige's syndrome, J. Neuropsychiatry Clin Neurosci. 21(2), 225.
DOI
|
7 |
Suarez, D., Haro, J.M., Novick, D., Perrin, E., Ochoa, S., Naber, D., 2009. Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia, Pharmacopsychiatry. 42(4), 135-40.
DOI
|
8 |
Tatsuya, I. et al., 1999. Preparation and evaluation of tablets rapidly disintegrating in saliva containing bitter-taste masked granules by the compression method, Chem. Pharm. Bull., 47(10), 1451.
DOI
ScienceOn
|
9 |
Viana, B.D., Prais, H.A., Nicolato, R., Caramelli, P., 2010. Posttraumatic brain injury psychosis successfully treated with olanzapine, Prog Neuropsychopharmacol Biol. Psychiatry. 34(1), 233-5.
|
10 |
Behere, R.V., Anjith, D., Rao, N.P., Venkatasubramanian, G., Gangadhar, B.N., 2009. Olanzapine-induced clinical seizure: a case report, Clin Neuropharmacol. 32(5), 297-8.
DOI
|
11 |
Costa, P., Lobo, J.M.S., 2001. Modeling and comparison of dissolution profiles, European J. Pharm. Sciences, 13, 123-133.
DOI
|
12 |
Chang, C.H., Hsiao, Y.L., Hsu, C.Y., Chen, S.T., 2009. Treatment of catatonia with olanzapine: A case report, Prog Neuropsychopharmacol Biol Psychiatry. 33(8), 1559-60.
DOI
|
13 |
Cipriani, A.., Rendell, J., Geddes, J.R., 2009. Olanzapine in the long-term treatment of bipolar disorder: A systematic review and meta-analysis, J. Psychopharmacol. 9(8), 1247-58.
|
14 |
Collin, A., Clevenot, D., Moulin, P., Macabeo, C., David, J.S., 2009. Acute pancreatitis induced by olanzapine. 28(10), 907-9.
DOI
ScienceOn
|
15 |
FDA SUPAC Guideline, Guidance for Industry, Immediate Release Solid Oral Dosage Forms, Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In vitro Dissolution Testing, and In vivo Bioequivalence.
|
16 |
Gohel, M., Patel, M., Amin, A., Agrawal, R., Dave, R., Bariya, N., 2004. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique, AAPS Pharm Sci Tech, 5(3), 1-6.
DOI
|